Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from AstraZeneca

AstraZeneca withdraws Covid-19 vaccine worldwide, citing surplus of newer vaccines

Pharmaceutical company says newer shots led to decline in demand for AstraZeneca vaccine, which is no longer being manufactured or supplied

The Guardian - AU

The crucial role of accountability in healthcare: Lessons from the Covishield vaccine

In recent times, the field of healthcare has been under scrutiny like never before. The COVID-19 pandemic has not only brought medical challenges but has also highlighted the critical need for accountability in the healthcare field. AstraZeneca's statement regarding rare adverse effects related to blood clotting associated with its COVID-19…

The Times of India

No adverse effects reported from COVID vaccines in India: V. K. Saraswat

No adverse effects have been reported in India with regard to the vaccines used for battling COVID-19, senior scientist and NITI Aayog member V. K. Saraswat said here on Saturday.

The Hindu

From analysis to the latest developments in health,
read the most diverse news in one place.

Is This Dividend Stock a Buy Now?

With a robust portfolio, this top pharma stock is a good mix of growth and income.

Barchart

Families 'give up legal action' against Astrazeneca after Covid vaccine blood clot deaths

Twelve families have dropped their cases, according to reports

Evening Standard

Covishield under scanner: Is Covaxin safe?

AstraZeneca's statement in court papers has sparked health concerns worldwide, especially in countries like India where COVISHIELD has been given to a large part of the population. The British pharmaceutical giant has admitted that its COVID vaccine can lead to a rare side effect called TTS or Thrombosis with Thrombocytopenia…

The Times of India

In India, all vaccine-related AEFI are routinely monitored and COVID is no exception, says health expert

All ‘Adverse Events Following Immunisation’ (AEFI) after COVID-19 vaccinations continue to be monitored, a senior official said.

The Hindu

Read news from The Economist, FT, and more,
with one subscription

"Safety is primary focus for all our vaccines": Covaxin-developer Bharat Biotech amid reports on AstraZeneca vaccine

Amid reports over potential rare side effects of the AstraZeneca-Oxford COVID-19 vaccine, Bharat Biotech, which developed the Covaxin, said in a statement that the vaccine was developed with a "single-minded focus on safety first." Read further on Dynamite News:

Dynamite News

Covishield | Plea in Supreme Court for probe panel for vaccine’s ‘risk factors’

Controversy over Covishield safety reaches Supreme Court, petition seeks expert panel to study risk factors and vaccine consequences.

The Hindu

AstraZeneca's £18.7m boss Soriot bounces back as pharma giant reveals 18% sales growth

Soriot came under fire this month for his £18.7 million pay packet

Evening Standard

There's still plenty of shares to like on the poor old FTSE 100

City Voices: Taken together, London’s top flight mightn’t look so appealing. But that doesn’t mean that all UK stocks should be written off.

Evening Standard

3 Biotech Stocks with Potential Gains - Watch or Buy?

The biotech industry’s growth prospects look promising due to advanced technologies like AI, the growing popularity of tailored treatments, a rise in chronic diseases, and higher R&D spending. Let's analyze the investment prospects of biotech stocks Innoviva (INVA), Organogenesis Holdings (ORGO), and Compugen (CGEN). Read more.

StockNews.com

The danger in saying yes to Pascal Soriot’s pay rise at AstraZeneca

Despite rebellion, approval of £18.7m package opens door to likelihood of US-style executive pay elsewhere

The Guardian - UK

Astrazeneca Shareholders Approve CEO Pay Policy For 2024

AstraZeneca shareholders approve 2024 pay policy, showing confidence in CEO Soriot's leadership and company's future growth.

Top News

Get all your
news in one place.

100’s of premium titles.
One news app.

The Guardian - UK

AstraZeneca CEO’s £18.7m pay approved despite shareholder rebellion

Third of voters reject Pascal Soriot’s deal but some say it is deserved as he had been ‘massively underpaid’

Evening Standard

FTSE 100 Live 11 April: Shares edge lower before ECB rates ca, Lok'nStore bought out by Shurgard for £378m

A new pay deal for AstraZeneca boss Pascal Soriot and the fallout from yesterday’s US inflation shock are among areas of focus for London traders.

Barchart

Next-Gen Cancer Therapies Could Spark Upside for AstraZeneca Stock

Next-generation cancer therapies are here. AstraZeneca - already an oncology leader - is going down the path of radiopharmaceuticals with its purchase of Fusion. Along with the other potential blockbuster drugs in its pipeline, this should bode well for growth at AZN.

Roll Call

Experts say Medicaid rebate change is behind inhaler price cuts - Roll Call

Three inhaler manufacturers will cap patient copays for their inhalers at $35 a month and lower the list prices of some of those products.

Get all your
news in one place.

100’s of premium titles.
One news app.

The Guardian - UK

AstraZeneca to buy Canadian cancer specialist Fusion for $2.4bn

Britain’s biggest drugmaker’s latest acquisition will help it to develop new radiotherapy treatments

The Guardian - UK

When £17m isn’t enough: FTSE firms plead to pay bosses millions more

Confronted by the huge salaries on offer in the US, London boardrooms are lobbying to be allowed to make their own bosses even wealthier

The Guardian - UK

‘A cut-and-paste budget’: UK businesses attack lack of help from chancellor

Hospitality trade says chancellor failed to help save sector with VAT cut, while travel industry laments air duty rise

Barchart

2 Obesity Treatment Stocks Morgan Stanley Likes More than Novo Nordisk

While Novo Nordisk's Wegovy currently dominates the obesity treatment market, Morgan Stanley sees more upside potential for LLY and AZN stocks going forward.

The Guardian - UK

A quiet conspiracy is afoot to give FTSE 100 executives a pay rise

As the London market’s woes are blamed on remuneration, a new US benchmark is emerging

Salon

Large COVID-19 vaccine study finds risks

Any pharmaceutical has risk of side effects, but a COVID infection is far more dangerous than the vaccines

The Guardian - AU

Two very rare Covid vaccine side-effects detected in global study of 99 million

Results confirm how uncommon known complications are as researchers confirm benefits from vaccines still ‘vastly outweigh the risks’

1 … 9 10 11 12

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.